Dr. Lal PathLabs Announces Second Interim Dividend and 1:1 Bonus Share Issue

Dr. Lal Path Labs , a leading diagnostic and related healthcare service provider, has made two significant announcements that may benefit its shareholders.

Second Interim Dividend Declaration

The Board of Directors of Dr. Lal PathLabs, in their meeting held on October 31, 2025, approved a second interim dividend of INR 7.00 per equity share. This dividend represents 70% of the face value of INR 10.00 per share for the financial year 2025-26.

Key details of the dividend:

Record Date: November 7, 2025
Payout Timeline: Within 30 days of declaration

The company had already paid an interim dividend of INR 6.00 per share earlier in the financial year, which was disbursed on August 14, 2025.

Bonus Share Issue

In addition to the dividend, the company has also announced a bonus share issue in the ratio of 1:1. This means shareholders will receive one new fully paid-up equity share for every existing share they hold.

Important points regarding the bonus issue:

Ratio: 1:1 (One bonus share for every one share held)
Face Value: INR 10.00 per share
Subject to: Shareholders', statutory, and regulatory approvals

The record date for determining the eligibility of shareholders for the bonus shares will be announced in due course.

Increase in Authorized Share Capital

To facilitate the bonus issue, the company plans to increase its authorized share capital from INR 1,07,96,00,000 to INR 2,00,00,00,000, subject to shareholders' approval.

Financial Implications

The bonus shares will be issued from the company's Securities Premium Account, which stood at INR 1,247.85 Million as per the audited financial statements for the year ended March 31, 2025.

Particulars	Pre-Bonus	Post-Bonus
Authorized Capital	1,07,96,00,000	2,00,00,00,000
Issued, Subscribed and Paid-up Capital	83,77,55,100	1,67,55,10,200
Number of Equity Shares	8,37,75,510	16,75,51,020

The company expects to credit/dispatch the bonus shares within two months from the date of board approval, i.e., by December 30, 2025.

Recent Financial Performance

For the quarter ended September 30, 2025, Dr. Lal PathLabs reported:

Consolidated revenue: INR 7,548.00 million
Profit after tax: INR 1,333.00 million

Investors should note that while bonus shares increase the number of shares held, they do not affect the company's underlying value. However, such corporate actions often lead to increased liquidity and broader shareholding base.

Shareholders are advised to consider their individual financial situations and consult with their financial advisors before making investment decisions based on these corporate announcements.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+1.49%	+2.86%	+0.56%	+13.23%	+0.72%	+37.62%

Dr. Lal Path Labs , a leading diagnostic and healthcare service provider, has reported strong financial results for the second quarter, along with an announcement of a bonus share issue.

Q2 Financial Highlights

Dr. Lal PathLabs has demonstrated robust growth in its Q2 performance:

Metric	Q2 Value (in billion rupees)	Year-over-Year Change
Revenue	7.30	↑ from 6.60
EBITDA	2.24	↑ from 2.02
Consolidated Net Profit	1.51	↑ from 1.30

The company maintained a healthy EBITDA margin of 30.7%, showcasing its operational efficiency.

Bonus Share Announcement

The Board of Directors has approved a bonus share issue in the ratio of 1:1. This means shareholders will receive one new fully paid-up equity share for every existing share held.

Key details of the bonus issue include:

Ratio: 1:1 (One bonus share for each existing share)
Face Value: INR 10 per share
Eligibility: Shareholders as of the yet-to-be-announced record date
Issuance: Subject to shareholder and regulatory approvals

Additional Corporate Actions

The company has also declared other significant corporate actions:

Interim Dividend: A second interim dividend of INR 7 per equity share (70% on face value of INR 10) for the financial year 2025-26.
Increase in Authorized Share Capital: The company plans to increase its authorized share capital from INR 1,07,96,00,000 to INR 2,00,00,00,000, subject to shareholder approval.
Employee Stock Option Plan: Introduction of "Dr. Lal PathLabs Employee Restricted Stock Unit Plan 2025" (RSU 2025), allocating options from the existing Employee Stock Option Plan 2022.

Market Implications

The combination of strong financial performance and shareholder-friendly actions like the bonus issue may potentially boost investor confidence in Dr. Lal PathLabs. The bonus issue could increase the liquidity of the stock without affecting the company's valuation.

As the healthcare sector continues to be a focus area for investors, Dr. Lal PathLabs' performance and strategic decisions may be closely watched by market participants for indications of broader sector trends.

Investors and shareholders should note that the record date for the bonus issue and other corporate actions will be announced in due course, and all actions are subject to necessary approvals.